2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-173013
    TWH106 98%
    TWH106 is an inhibitor for Cyclophilin (Cyp) that exhibits good affinity to CypA and CypB with KD of 53 nM and 139 nM. TWH106 inhibits the replication of HIV and HCV, exhibiting antiviral activity.
    TWH106
  • HY-173018
    ML283 1403245-31-7 98%
    ML283 is a HCV NS3 helicase inhibitor (IC50: 2.6 μM). ML283 also inhibits DenV ATPase (IC50: 4.0 μM).
    ML283
  • HY-173021
    Succinate dehydrogenase-IN-7 98%
    Succinate dehydrogenase-IN-7 (Compound 2f) is a Succinate dehydrogenase inhibitor (IC50 = 2.51 μM). Succinate dehydrogenase-IN-7 has fungicidal activity.
    Succinate dehydrogenase-IN-7
  • HY-173027
    SPB07935 634190-75-3 98%
    SPB07935 inhibits the plasmepsin II in Plasmodium falciparum and can be used as an antimalarial agent. SPB07935 regulates the life cycle of P. falciparum, inhibits the growth of Plasmodium strains FcB1 and 3D7 with IC50 of 8 μM and 4.7 μM.
    SPB07935
  • HY-173028
    RH01201 300664-41-9 98%
    RH01201 is the non-competitive inhibitor for plasmepsin II with a Ki of 123 μM.
    RH01201
  • HY-173050
    NEU-1017 1800426-38-3 98%
    NEU-1017 is a broad-spectrum antiparasitic agent. NEU-1017 inhibits T. brucei, L. major, and P. falciparum with EC50 values of 210 nM, 240 nM, and 3 nM, respectively. X
    NEU-1017
  • HY-173051
    Antiparasitic agent-24 98%
    Antiparasitic agent-24 (Compound 14a) is an antiparasitic agent, with EC50s of 0.005 μM (L. maj), 0.069 μM (L. don), 0.82 μM (T. brucei), 4.1 μM (T. cruzi) respectively.
    Antiparasitic agent-24
  • HY-173054
    FtsZ-IN-12 98%
    FtsZ-IN-12 (Compound 16e) is the inhibitor for filamentous temperature-sensitive mutant Z (FtsZ) that promotes the polymerization of FtsZ protein, inhibits its GTPase activity, thereby interfering with bacterial cell division process. FtsZ-IN-12 exhibits boardspectrum antibacterial activity that inhibits B. subtilis ATCC9372, B. pumilus CMCC63202, S. aureus ATCC25923, E. coli BW25113 and A. baumannii ATCC19606 with MIC of 0.062-1 μg/mL. FtsZ-IN-12 inhibits the formation of bacterial biofilms and exhibits a clearing effect on mature biofilms. FtsZ-IN-12 exhibits bactericidal activity without hemolytic toxicity to mammalian red blood cells (15 mg/kg).
    FtsZ-IN-12
  • HY-173071
    DprE1-IN-13 98%
    DprE1-IN-13 (Compound 42) is the inhibitor for decaprenyl-phosphoryl-β-d-ribose oxidase (DprE1) with IC50 of 12.72 μM. DprE1-IN-13 inhibits Mycobacterium tuberculosis H37Ra with MIC50 of 1.071 μM.
    DprE1-IN-13
  • HY-173073
    Insecticidal agent 20 98%
    Insecticidal agent 20 (Compound 17) is an insecticide that can bind to AChBP. Insecticidal agent 20 exhibits good insecticidal activity against the larvae (LC50: 1.57 ppm) and pupae (LC50: 4.17 ppm) of Culex pipiens.
    Insecticidal agent 20
  • HY-173077
    PD-L1/LpxC-IN-1 98%
    PD-L1/LpxC-IN-1 (Conpound 12b) is the inhibitor for PD-L1 and LpxC with IC50 of 5.2 μM and 0.081 μM. PD-L1/LpxC-IN-1 inhibits the biosynthesis of bacterial lipopolysaccharide, causes the lysis and death of bacterial cells. PD-L1/LpxC-IN-1 inhibits Gram-negative bacteria, MIC for K. pneumoniae ATCC 13883, E. coli ATCC 8739, S. typhimurium ATCC 14028 and P. aeruginosa ATCC 9027 is 0.25-0.5 μg/mL. PD-L1/LpxC-IN-1 downregulates the expression of inflammatory factors IL-2 and IFN-γ, upregulates the expression of CD4+ and CD8+ cells, thereby activating the immune system and inhibiting excessive inflammatory responses. PD-L1/LpxC-IN-1 exhibits antibacterial activity in K. pneumoniae ATCC 13883 infected mouse models.
    PD-L1/LpxC-IN-1
  • HY-173080
    Antibacterial agent 267 98%
    Antibacterial agent 267 (Compound h19) is a pleuromutilin derivative with a potent antibacterial activity on Gram-positive bacteria. Antibacterial agent 267 shows an antibacterial activity in methicillin-resistant Staphylococcus aureus (MRSA)-infected mouse models.
    Antibacterial agent 267
  • HY-173081
    4"-(2-(p-Chlorophenyl)acetoxyl)spiramycin 98%
    4"-(2-(p-Chlorophenyl)acetoxyl)spiramycin (Compound 2d) is a broad-spectrum anti-coronaviral agent via targeting frameshifting element (FSE). 4"-(2-(p-Chlorophenyl)acetoxyl)spiramycin inhibits HCoV-OC43 and HCoV-229E with EC50 values of 0.85 μM and 1.45 μM. 4"-(2-(p-Chlorophenyl)acetoxyl)spiramycin shows a dual-target mechanism that acts on both viral FSE RNA and host DIS3L2.
    4
  • HY-173120
    HBV-IN-51 98%
    HBV-IN-51 (Compound 17e) is a potent HBV capsid assembly modulator. HBV-IN-51 exhibits remarkable anti-HBV activity with an EC50 of 0.033 μM in HepAD38 cells. HBV-IN-51 exhibits robust metabolic stability in plasma, and can be rapidly metabolized in human liver microsomes.
    HBV-IN-51
  • HY-173121
    KR019 98%
    KR019 is a potent HBV capsid assembly modulator, exhibits potent antiviral activity in HBV-replicating cells. KR019 binds to the hydrophobic pocket at the core protein dimer-dimer interface, misdirecting capsid assembly into genome-free capsids and thereby inhibiting viral replication.
    KR019
  • HY-173128
    TZOA 2106826-77-9 98%
    TZOA is an antiviral agent that inhibits the replication of infectious hematopoietic necrosis virus (IHNV) in a dose-dependent manner and significantly reduces viral titers. TZOA can effectively counteract IHNV-induced apoptosis, maintain mitochondrial membrane potential and homeostasis, and restore MAVS-mediated interferon expression. TZOA has antiviral activity.
    TZOA
  • HY-173134
    SARS-CoV-2 RdRp-IN-1 98%
    SARS-CoV-2 RdRp-IN-1 (Compound PAP-2) is a potent SARS-CoV-2 RdRp inhibitor, with an EC50 of 1.11 μM. SARS-CoV-2 RdRp-IN-1 can bind directly to SARS-CoV-2 RdRp, fully resistance to the exoribonuclease (ExoN) and exhibit broad spectrum anti-CoV activities.
    SARS-CoV-2 RdRp-IN-1
  • HY-173148
    TKB272 2892688-18-3 98%
    TKB272 is an orally active and selective antiviral agent targeting the main protease (Mpro) of SARS-CoV-2. It effectively blocks the infection and replication of various SARS-CoV-2 strains, including Omicron variants such as XBB.1.5 and EG.5.1. The enzymatic inhibitory activity of TKB272 shows an IC50 of 0.7 µM (against SARS-CoV-2WK-521 Mpro), and its antiviral activity at the cellular level reaches an EC50 as low as 2.6 nM (against BQ.1.1 strain in HeLahACE2-TMPRSS2 cells), with a cytotoxicity CC50 of 98 µM, indicating no apparent toxicity. In addition, TKB272 significantly suppresses the replication of SARS-CoV-2XBB.1.5 in B6.Cg-Tg(K18-hACE2)2-Prlmn/J transgenic mouse models. TKB272 holds promise for research in the field of SARS-CoV-2 infection.
    TKB272
  • HY-173189
    2-5A 65954-93-0
    2-5A is a 5'-triphosphorylated (2',5') oligoadenylate. 2-5A degrades viral mRNA and inhibits protein synthesis by binding to RNase L and activating its endoribonuclease activity. 2-5A can be used in antiviral research.
    2-5A
  • HY-173192
    Antibacterial agent 272 98%
    Antibacterial agent 272 (Compound Z22) is a potential antimicrobial agent targeting DNA and the DNA-topoisomerase II (DNA-Topo II) complex, exhibiting MIC values of 1 μg/mL against Staphylococcus aureus 25923 and 29213, 2 μg/mL against Staphylococcus epidermidis 12228, 2-4 μg/mL against Enterococcus faecalis, and 4 μg/mL against Pseudomonas aeruginosa 9027 and 27853, demonstrating potent antibacterial activity. This compound functions by intercalating with DNA base pairs to disrupt normal bacterial DNA function, making it suitable for research on bacterial infectious diseases.
    Antibacterial agent 272
Cat. No. Product Name / Synonyms Application Reactivity